Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MERIDIA

« Back to Dashboard
Meridia is a drug marketed by Abbott and is included in one NDA.

The generic ingredient in MERIDIA is sibutramine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the sibutramine hydrochloride profile page.

Summary for Tradename: MERIDIA


Clinical Trials for: MERIDIA

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
Status: Completed Condition: Obesity

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
Status: Completed Condition: Obesity

Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects
Status: Completed Condition: Healthy

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients
Status: Active, not recruiting Condition: Obesity

Studying the Effects of Sibutramine on Eating Behavior
Status: Terminated Condition: Obesity

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Status: Completed Condition: Obesity; Hypertension

Treatment of Binge Eating in Obese Patients in Primary Care
Status: Completed Condition: Obesity; Binge Eating

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
Status: Completed Condition: Obesity

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects
Status: Terminated Condition: Obesity; Weight Loss

Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
Status: Completed Condition: Obesity

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
sibutramine hydrochloride
CAPSULE;ORAL020632-001Nov 22, 1997DISCNNo<disabled><disabled>
sibutramine hydrochloride
CAPSULE;ORAL020632-002Nov 22, 1997DISCNNo<disabled><disabled>
sibutramine hydrochloride
CAPSULE;ORAL020632-003Nov 22, 1997DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MERIDIA

Drugname Dosage Strength RLD Submissiondate
sibutramine hydrochlorideCapsules10 mg and 15 mgMeridia8/14/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn